Fairvalue-Calculator Fairvalue-Calculator
EN DE

Lytix Biopharma ASA (LYTIX) Fair Value & Analysis

Healthcare · NO · Market cap 811M NOK

Pricekr 9.24
Fair Valuekr 3.61
Upside-60.9%
Quality95/100
Evidence: Low Range kr 2.71 – kr 4.52

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Lytix Biopharma ASA (LYTIX) currently trades at kr 9.24, while our model-based Fair Value estimate is kr 3.61 — implying the stock looks roughly 60.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of ruxotemitide for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma ASA was founded in 2003 and is based in Oslo, Norway.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Lytix Biopharma ASA (LYTIX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 3.61 versus a price of kr 9.24 — about −61% (overvalued). Model-based estimate, not financial advice.
What is the fair value of LYTIX?
Our 21-model fair value for Lytix Biopharma ASA is kr 3.61 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 9.24.
What is the quality score of LYTIX?
Lytix Biopharma ASA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.